What Is Retatrutide?
Retatrutide (LY3437943) is a 39-amino acid peptide built on a GIP peptide backbone, conjugated to a C20 fatty diacid moiety via a linker that enables albumin binding. It functions as a triple agonist, targeting three distinct G-protein-coupled receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) receptors. Key amino acid modifications — including 2-aminoisobutyric acid (Aib) at positions 2 and 13, 2-methylleucine, and an L-serinamide at the C-terminus — confer resistance to DPP-4 degradation. This triple-receptor approach distinguishes retatrutide from existing therapies such as semaglutide (a single GLP-1 agonist) and tirzepatide (a dual GIP/GLP-1 agonist).
Retatrutide's receptor potency profile is GIP-primary: EC50 values are 0.0643 nM at the GIP receptor (most potent), 0.775 nM at GLP-1, and 5.79 nM at glucagon. Compared to endogenous ligands, this translates to approximately 8.9-fold greater potency at the human GIP receptor, with 0.4-fold and 0.3-fold relative potency at GLP-1 and glucagon receptors, respectively. The pharmacokinetics support once-weekly dosing, with a half-life of approximately 6 days and steady state reached in 4-5 weeks at each dose level.The primary human-use benefits observed in clinical research include:
- Substantial weight reduction (up to 24.2% in Phase 2 and 28.7% in preliminary Phase 3 data)
- Improved glycemic control and HbA1c reduction (up to -2.0% in Phase 3)
- Decreased waist circumference
- Improvements in liver fat levels (up to 82.4% reduction) and lipid profiles
How Retatrutide Compares
| Semaglutide (Wegovy) | Tirzepatide (Zepbound) | Retatrutide | |
|---|---|---|---|
| Mechanism | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Max Weight Loss | ~15.2% (STEP 1, 68 wk) | ~22.5% (SURMOUNT-1, 72 wk) | 24.2% (Phase 2, 48 wk) / 28.7% (Phase 3 topline, 68 wk) |
| Max Dose | 2.4 mg weekly | 15 mg weekly | 12 mg weekly |
| Half-Life | ~7 days | ~5 days | ~6 days |
| FDA Status | Approved (2021) | Approved (2023) | Investigational |
| Dosing | Once weekly | Once weekly | Once weekly |
Cross-trial comparisons have inherent limitations due to differences in study populations, trial design, and endpoints. For detailed head-to-head analysis, see semaglutide vs retatrutide and tirzepatide vs retatrutide.
How It Works
GLP-1 Receptor Activation
The GLP-1 receptor agonism component of retatrutide promotes weight loss through multiple pathways. GLP-1 receptor activation suppresses appetite, enhances satiety, and delays gastric emptying. Additionally, GLP-1 stimulation enhances glucose-dependent insulin secretion, directly improving glycemic control while reducing glucagon release between meals.
GIP Receptor Activation
Glucose-dependent insulinotropic polypeptide (GIP) receptor activation complements GLP-1 effects by further enhancing insulin secretion in response to nutrient intake. The synergistic combination of GIP and GLP-1 agonism has demonstrated superior efficacy compared with GLP-1 alone, as evidenced by tirzepatide's performance relative to semaglutide (see the semaglutide vs tirzepatide breakdown).
Glucagon Receptor Activation
The glucagon receptor agonism represents retatrutide's distinguishing feature. Glucagon receptor activation in obese patients increases energy expenditure through thermogenic effects, promotes hepatic lipid oxidation, and may enhance substrate utilization. However, the magnitude and consistency of this effect remain under investigation. Research also suggests glucagon agonism contributes to reductions in LDL cholesterol (approximately 20%) through effects on PCSK9 degradation.
Synergistic Triple-Receptor Effects
The simultaneous activation of all three receptors produces synergistic metabolic effects: appetite suppression, increased energy expenditure, improved glucose homeostasis, and enhanced fat oxidation. This multi-target approach addresses obesity through complementary mechanisms that single or dual agonists cannot achieve alone.
Secondary metabolic outcomes from clinical trials support the multi-system benefits of triple-receptor activation. Retatrutide 12 mg reduced triglycerides by 40.6%, non-HDL cholesterol by 26.9%, and apolipoprotein B (ApoB) by 24.2%. Among participants on antihypertensive medications, 41% of those on the 8 mg dose were able to discontinue blood pressure medications. Heart rate increased by approximately 6.7 bpm at the 12 mg dose, consistent with glucagon-mediated sympathetic activation.
“The inclusion of glucagon receptor agonism is pharmacologically bold — glucagon has historically been avoided in metabolic therapy due to its hyperglycemic effects, but retatrutide's concurrent GLP-1 and GIP activation effectively counterbalances this, allowing clinicians to harness glucagon's thermogenic and lipolytic benefits without compromising glycemic control.”
